Modern approaches to the diagnostics, treatment and prevention of severe community-acquired pneumonia in adults: a review
PDF_2021-3_27-46 (Русский)
HTML_2021-3_27-46 (Русский)


community-acquired infections
anti-bacterial agents
respiratory therapy

How to Cite

Avdeev SN, Belotserkovskiy BZ, Dehnich AV, Zaytsev AA, Kozlov RS, Protsenko DN, Ratchina SA, Sinopalnikov AI, Yakovlev SV, Yaroshetskiy AI Modern approaches to the diagnostics, treatment and prevention of severe community-acquired pneumonia in adults: a review. Annals of Critical Care. 2021;(3):27–46. doi:10.21320/1818-474X-2021-3-27-46.


Abstract Views: 16
PDF_2021-3_27-46 (Русский) Downloads: 3
HTML_2021-3_27-46 (Русский) Downloads: 1
Plum Analytics


English Русский

Social Networks




The article provides an overview of literature on severe community-acquired pneumonia (CAP) and the most recent data on the epidemiology and etiology of CAP, and describes the antibiotic susceptibility of Streptococcus pneumoniae — the leading causative agent of CAP. The article discusses demonstrative diagnostic data and emphasizes the need to determine as early as possible the oxygen saturation of arterial blood using a pulse oximeter, as well as to dynamically measure the concentration of inflammatory markers in blood and carry out a comprehensive microbiological examination. The authors argue for the advantages of computed tomography over conventional x-ray examination and point out the usefulness of ultrasound to diagnose and dynamically assess the condition of lung tissue in the course of treatment. The article also provides up-to-date recommendations for the differential antibiotic treatment of severe CAP patients based on the existence of risk factors making them susceptible to the infection with certain microorganisms, and suggests etiotropic therapy regimens for cases where the causative agent has been identified. It also emphasizes the need for a timely prescription of combined antibiotic therapy with intravenous administration, suggesting the possibility of de-escalation based on microbiological data. A substantial portion of the overview focuses on the respiratory therapy for CAP, outlining a graded algorithm for the treatment of acute respiratory failure based on stage, and describing in detail the most effective and safe invasive and non-invasive respiratory support strategies. The proposed adjuvant therapies include glucocorticosteroids if it is impossible to stabilize hemodynamics by means of adequate hydration and vasopressor support, as well as parenteral anticoagulants to prevent thromboembolic complications. Pneumococcal and influenza vaccines are suggested as CAP prevention strategies for high-risk patients. The publication seeks to highlight the most critical aspects of the draft of the updated clinical recommendations for CAP and encourage their wide discussion across the community of Russian intensive care anesthesiologists and intensivists.
PDF_2021-3_27-46 (Русский)
HTML_2021-3_27-46 (Русский)


  1. Cilloniz C., Dominedo C., Garcia-Vidal C., Torres A. Community-acquired pneumonia as an emergency condition. Curr Opin Crit Care. 2018; 24(6): 531–39. DOI: 10.1097/MCC.0000000000000550
  2. Александрова Г.А., ГолубевН.А., Тюрина Е.М. и др. Заболеваемость взрослого населения России в 2019 г. с диагнозом, установленным впервые в жизни. Статистические материалы, часть М., 2020. — 140 с. [Aleksandrova G.A., Golubev N.A., Tyurina E.M., et al. The incidence of the adult population of Russia in 2019 with a diagnosis established for the first time in life. Statistical materials, part III. Moscow, 2020. 140 pp. (In Russ)]
  3. О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в2020 году: Государственный доклад. М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2021. 256 с. Доступно по адресу: [Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing. On the state of the sanitary-epidemiological well-being of the population in the Russian Federation in 2020. State report. Available at: https://rospotrebnadzor. ru/documents/details.php?ELEMENT_ID=18266. (In Russ)]
  4. Global action plan for prevention and control of pneumonia (GAPP): technical consensus statement. Geneva: World Health Organization; 2009. Available from:
  5. Статистические материалы Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (Форма 2). Москва, 2019. [Statistical materials of the Federal Service for Surveillance on Consumer Rights Protection and Human Welfare (Form 2).Moscow, 2019. (In Russ)]
  6. Mandell L.M., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis. 2007; 44(Suppl 2): S27–72. DOI: 10.1086/511159
  7. Ewig S., Woodhead M., Torres A. Towards a sensible comprehension of severe community-acquired pneumonia. Intensive Care Med 2011; 37: 214–23. DOI: 10.1007/s00134-010-2077-0
  8. Marti C., Garin N., Grosgurin O., et al. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care. 2012; 16(4): R141. DOI: 10.1186/cc11447
  9. Chalmers J.D., Mandal P., Singanayagam A., et al. Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med 2011; 37: 1409–20. DOI: 10.1007/s00134-011-2261-x
  10. Jain S., Self W.H., Wunderink R.G., et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015; 373: 415–27. DOI: 10.1056/NEJMoa1500245
  11. Ito A., Ishida T., Tokumasu H., et al. Prognostic factors in hospitalized community-acquired pneumonia: a retrospective study of a prospective observational cohort. BMC Pulm Med. 2017; 17(1): 78. DOI: 10.1186/s12890-017-0424-4
  12. Walden A.P., Clarke G.M., McKechnie S., et al. Patients with community acquired pneumonia admitted to European intensive care units: an epidemiological survey of the GenOSept cohort. Crit Care. 2014; 18(2): R58. DOI: 10.1186/cc13812
  13. Vallés J., Diaz E., Martín-Loeches I., et al. Evolution over a 15-year period of the clinical characteristics and outcomes of critically ill patients with severe community-acquired pneumonia. Med Intensiva 2016; 40(4): 238–45. DOI: 10.1016/j.medin.2015.07.005
  14. Espinoza R., Lapa e Silva J.R., Bergmann A. Factors associated with mortality in severe community-acquired pneumonia: A multicenter cohort study. J Crit Care 2019; 50: 82–6. DOI: 10.1016/j.jcrc.2018.11.024
  15. Woodhead M., Welch C.A., Harrison D.A., et al. Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Crit Care. 2006; 10(Suppl 2): S1. DOI: 10.1186/cc4927
  16. ЧучалинА.Г., Синопальников А.И., Козлов Р.С. и др. Российское респираторное общество (РРО) «Межрегиональная ассоциация по клинической микробиологии и антимикробной химиотерапии» (МАКМАХ). Клинические рекомендации по диагностике, лечению и профилактике тяжелой внебольничной пневмонии у взрослых. Пульмонология. 2014; 14(4): 13–48. DOI: 18093/0869-0189-2014-0-4-13-48 [Chuchalin A.G., Sinopalʼnikov A.I., Kozlov R.S., et al. Russian Respiratory Society Interregional association on clinical microbiology and antimicrobial chemotherapy Clinical guidelines on diagnosis, treatment and prevention of severe community-acquired pneumonia in adults. Pulmonologiya. 2014;(4): 13–48. (In Russ)]
  17. Torres A., Blasi F., Peetermans W.E., et al. The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. Eur J Clin Microbiol Infect Dis. 2014; 33(7): 1065–79. DOI; 10.1007/s10096-014-2067-1
  18. Johansson N., Kalin M., Tiveljung-Lindell A., et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis. 2010; 50(2): 202–9. DOI: 10.1086/648678
  19. Athlin S., Lidman C., Lundqvist A., et al. Management of community-acquired pneumonia in immunocompetent adults: updated Swedish guidelines 2017. Infect Dis (Lond). 2018; 50(4): 247–72. DOI: 10.1080/23744235.2017.1399316
  20. ЗахаренковИ.А., Рачина С.А., Дехнич Н.Н. и др. Этиология тяжелой внебольничной пневмонии у взрослых: результаты первого российского многоцентрового исследования. Терапевтический архив. 2020; 92(1): 36–42. DOI: 10.26442/00403660.2020.01.000491 [Zakharenkov I.A., Rachina S.A., Dekhnich N.N., et al. Etiology of severe community-acquired pneumonia in adults: results of the first Russian multicenter study. Therapeutic Archive. 2020; 92(1): 36–42. (In Russ)]
  21. Pavia A.T. What is the role of respiratory viruses in community-acquired pneumonia? What is the best therapy for influenza and other viral causes of community-acquired pneumonia? Infect Dis Clin North Am. 2013; 27(1): 157–75. DOI: 10.1016/j.idc.2012.11.007
  22. Choi S.H., Hong S.B., Ko G.B., et al. Viral infection in patients with severe pneumonia requiring intensive care unit admission. Am J Respir Crit Care Med. 2012; 186(4): 325–32. DOI: 10.1164/rccn.20112-2240OC
  23. Bjarnason A., Westin J., Lindh M., et al. Incidence, Etiology, and Outcomes of Community-Acquired Pneumonia: A Population-Based Study. Open Forum Infect Dis. 2018; 5(2): ofy010. DOI: 10.1093/ofid/ofy010
  24. РачинаС.А., Козлов Р.С., Шаль Е.П. и др. Структура бактериальных возбудителей внебольничной пневмонии в многопрофильных стационарах г. Смоленска. Пульмонология 2011; 1: 5–18. DOI: 10.18093/0869-1089-2011-0-1-5-18 [Rachina S.A., Kozlov R.S., Shal E.P., et al. A spectrum of causative bacterial pathogens in community-acquired pneumonia in multidisciplinary hospitals of Smolensk. Pulmonologiya. 2011; (1): 5–18. (In Russ)]
  25. Welte T., Torres A., Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012; 67(1): 71–9. DOI:10.1136/thx.2009.129502
  26. ЕжловаЕ.Б., Демина Ю.В., Шеенков Н.В. и др. Лабораторная диагностика внебольничных пневмоний. Методические указания МУК 4.2.3115-13. Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека. Москва, 2013. [Yezhlova E.B., Demina Yu.V., Sheenkov N.V., et al. Laboratory diagnosis of community-acquired pneumonia. Guidelines MUK 4.2.3115-13. Federal Service for the Oversight of Consumer Protection and Welfare. Moscow, 2013. (In Russ)]
  27. КузьменковА.Ю., Виноградова А.Г., Трушин И.В. и др. AMRmap — система мониторинга антибиотикорезистентности в России. Клин микробиол антимикроб химиотер. 2021; 23(2): 117–23. DOI: 10.36488/cmac.2021.2.117–23 [Kuzmenkov A.Yu., Vinogradova A.G., Trushin I.V., et al. AMRmap — antibiotic resistance surveillance system In Russia. Clin Microbiol Antimicrob Chemiother. 2021; 23(2): 117–23. (In Russ)]
  28. ИванчикН.И., Чагарян А.Н., Сухорукова М.В. и др. Антибиотикорезистентность клинических штаммов Streptococcus pneumoniae в России: результаты многоцентрового эпидемиологического исследования «ПеГАС 2014–2017». Клин микробиол антимикроб химиотер. 2019; 21(3): 230–7. DOI: 10.36488/cmac.2019.3.230-237 [Ivanchik N.V., Chagaryan A.N., Sukhorukova M.V., et al. Antimicrobial resistance of clinical Streptococcus pneumonia isolates In Russia; the results of multicenter epidemiological study “PEHASus 2014–2017”. Clin Microbiol Antimicrob Chemiother. 2019; 21(3): 230–37. (In Russ)]
  29. Woodhead M., Blasi F., Ewig S. and the ERS/ESCMID Task Force. Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol Infect. 2011; 17(Suppl. 6): 1–24. DOI: 10.1111/j.1469-0691.2011.03602.x
  30. КозловР.С. Пневмококки: уроки прошлого — взгляд в будущее. Смоленск: МАКМАХ, 2010. [Kozlov R.S. Pneumococci: past, present and future. Smolensk. IACMAC, 2010. (In Russ)]
  31. Thomas R., Ferguson J., Coombs G., et al. Community-acquired methicillin-resistant Staphylococcus aureus pneumonia: a clinical audit. Respirology. 2011; 16(6): 926–31. DOI: 10.1111/j.1440-1843.2011.01965.x
  32. Li H.T., Zhang T.T., Huang J., et al. Factors associated with the outcome of life-threatening necrotizing pneumonia due to community-acquired Staphylococcus aureus in adult and adolescent patients. Respiration 2011; 81(6): 448–60. DOI: 10.1159/000319557
  33. Синопальников А.И., Фесенко О.В. Внебольничная пневмония у взрослых. В кн.: Респираторная медицина. 2-е изд., перераб. и доп. Под ред. А.Г. Чучалина. М.: ГЭОТАР-Медиа, 2017. Т. 2. С. 29–67. [Sinopalnikov A.I., Fesenko O.V. Community-acquired pneumonia in adults. In: Respiratory Medicine, 2nd Ed. by Chuchalin A.G. Moscow: GEOTAR-Media, 2017. V. 2. P. 29–67. (In Russ)]
  34. РачинаС.А., Синопальников А.И. Инфекционные заболевания нижних дыхательных путей. В кн.: Основы внутренней медицины. Ред. В.С. Моисеев, Ж.Д. Кобалава, И.В. Маев и др. 2-е изд., перераб. и доп. М.: ООО «МИА», 2020. Т. 1. С. 145–69. [Rachina S.A., Sinopalnikov A.I. Lower respiratory tract infections. In: Fundamentals of Internal Medicine. Ed. V.S. Moiseev, Zh.D. Kobalava, I.V. Maev, et al. 2 ed., revised. and add. M: LLC «MIA», 2020. V. 1. 145–69 pp. (In Russ)]
  35. Bewick T., Greenwood S., Lim W.S. What is the role of pulse oximetry in the assessment of patients with community-acquired pneumonia in primary care? Prim Care Respir J. 2010; 19(4): 378–82. DOI: 10.4104/pcrj.2010.00049
  36. Blot S.I., Rodriguez A., Sole-Violan J., et al. Effects of delayed oxygenation assessment on time to antibiotic delivery and mortality in patients with severe community-acquired pneumonia. Crit Care Med. 2007; 35(11): 2509–14. DOI: 10.1097/01.CCM.0000287587.43801.9C
  37. Rhodes A., Evans L., Alhazzani W., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2016. Intensive Care Med. 2017; 43(3): 304–77. DOI: 10.1007/s00134-017-4683-6
  38. Howell M.D., Donnino M., Clardy P., et al. Occult hypoperfusion and mortality in patients with suspected infection. Intensive Care Med. 2007; 33(11): 1892–99. DOI: 10.1007/s00134-007-0680-5
  39. Zhou H., Lan T., Guo S. Prognostic Prediction Value of qSOFA, SOFA, and Admission Lactate in Septic Patients with Community-Acquired Pneumonia in Emergency Department. Emerg Med Int. 2020; 2020: 7979353. DOI: 10.1155/2020/7979353
  40. Tamayose M., Fujita J., Parrott G., et al. Correlations between extent of X-ray infiltration and levels of serum C-reactive protein in adult non-severe community-acquired pneumonia. J Infect Chemother. 2015; 21(6): 456–63. DOI: 10.1016/j.jiac.2015.02.009
  41. Schuetz P., Litke A., Albrich W.C., et al. Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia. Curr Opin Infect Dis. 2013; 26(2): 159–67. DOI: 10.1097/QCO.0b013e32835d0bec
  42. Nouvenne A., Ticinesi A., Folesani G., et al. The association of serum procalcitonin and high-sensitivity C-reactive protein with pneumonia in elderly multimorbid patients with respiratory symptoms: retrospective cohort study. BMC Geriatr. 2016; 16: 16. DOI: 10.1186/s12877-016-0192-7
  43. Nseir W., Farah R., Mograbi J., et al. Impact of serum C-reactive protein measurements in the first 2 days on the 30-day mortality in hospitalized patients with severe community-acquired pneumonia: a cohort study. J Crit Care. 2013; 28(3): 291–5. DOI: 10.1016/j.jcrc.2012.09.012
  44. Hedlund J., Hansson L.O. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection. 2000; 28(2): 68–73. DOI: 10.1007/s150100050049
  45. Johansson N., Kalin M., Backman-Johansson C., et al. Procalcitonin levels in community-acquired pneumonia — correlation with aetiology and severity. Scand J Infect Dis. 2014; 46(11): 787–91. DOI: 10.3109/00365548.2014.945955
  46. Schuetz P., Wirz Y., Sager R., et al. Procalcitonin to Initiate or Discontinue Antibiotics in Acute Respiratory Tract Infections. Cochrane Database Syst Rev. 2017; 10(10): CD007498. DOI: 10.1002/14651858CD007498.pub3
  47. de Jong E., van Oers J.A., Beishuizen A., et al. Efficacy and Safety of Procalcitonin Guidance in Reducing the Duration of Antibiotic Treatment in Critically Ill Patients: A Randomised, Controlled, Open-Label Trial. Lancet Infect Dis. 2016; 16(7): 819–27. DOI: 10.1016/S1473-3099(16)00053-0
  48. Menendez R., Martinez R., Reyes S., et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax. 2009; 64(7): 587–91. DOI: 10.1136/thx.2008.105312
  49. Sligl W.I., Marrie T.J. Severe Community-Acquired Pneumonia. Crit Care Clin. 2013; 29(3): 563–1. DOI: 10.1016/j.ccc.2013.03.009
  50. Рачина С.А., Иванчик Н.В., Козлов Р.С. Особенности микробиологической диагностики при внебольничной пневмонии у взрослых. Практическая пульмонология. 2016; 4: 40–7. [Rachina S.A., Ivanchik N.V., Kozlov R.S. Microbiology Diagnostics of Community-acquired Pneumonia in Adults. Practical pulmonology. 2016; 4:40–7. (In Russ)]
  51. Campbell S.G., Marrie T.J., Anstey R., et al. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. 2003; 123(4): 1142–50. DOI: 10.1378/chest.123.4.1142
  52. Министерство здравоохранения Российской Федерации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Временные методические рекомендации. Версия11 (07.05.2021). [Ministry of Health of the Russian Federation. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Temporary guidelines. Version 11 (05/07/2021). (In Russ)]
  53. Dunn J.J., Ginocchio C.C. Can newly developed, rapid immunochromatographic antigen detection tests be reliably used for the laboratory diagnosis of influenza virus infections? J Clin Microbiol. 2015; 53(6): 1790–6. DOI: 10.1128/JCM.02739-14
  54. Claessens Y.E., Debray M.P., Tubach F., et al. Early chest computed tomography scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia. Am J Respir Crit Care Med. 2015; 192(8): 974–82. DOI: 10.1164/rccm.201501-0017OC
  55. Hayden G.E., Wrenn K.W. Chest radiograph vs. computed tomography scan in the evaluation for pneumonia. J Emerg Med. 2009; 36(3): 266–70. DOI: 10.1016/j.jemermed.2007.11.042
  56. Chavez M.A., Shams N., Ellington L.E., et al. Lung ultrasound for the diagnosis of pneumonia in adults: a systematic review and meta-analysis. Respir Res. 2014; 15(1): 50. DOI: 10.1186/1465-9921-15-50
  57. Ye X., Xiao H., Chen B., et al. Accuracy of lung ultrasonography versus chest radiography for the diagnosis of adult community-acquired pneumonia: review of the literature and meta-analysis. PLoS One. 2015; 10(6): e0130066. DOI: 10.1371/journal.pone.0130066
  58. ПетровА.А., Сафарова А.Ф., Рачина С.А. и др. Ультразвуковое исследование легких: методика выполнения и перспективы в диагностике нозокомиальной пневмонии. Практическая пульмонология 2018; 3: 44–51. [Petrov A.A., Safarova A.F., Rachina S.A., et al. Ultrasound examination of the lungs: methodology and practical issues in the diagnosis of nosocomial pneumonia. Practical Pulmonology. 2018; 3: 44–51. (In Russ)]
  59. ЕфимоваВ.П., Рачина С.А., Вацик М.В. и др. Методика ультразвукового исследования легких: внедрение в клиническую практику в условиях многопрофильного стационара в книге: Премия города Москвы в области медицины. Под ред. Хрипуна А.И. М., 2019: 66–7. [Efimova V.P., Rachina S.A., Vatsik M.V., et al. Pulmonary ultrasound examination technique: introduction into clinical practice in a multidisciplinary hospital. Ed. by Khripun A.I. M., 2019: 66–7. (In Russ)]
  60. Lichtenstein D.A. BLUE-Protocol and FALLS-Protocol: Two applications of lung ultrasound in the critically ill. Chest. 2015; 147(6): 1659–70. DOI: 10.1378/chest.14-1313
  61. Restrepo M.I., Mortensen E.M., Rello J., et al. Late Admission to the ICU in Patients With Community-Acquired Pneumonia Is Associated With Higher Mortality. Chest. 2010; 137(3): 552–7. DOI: 10.1378/chest.09-1547
  62. Salih W., Schembri S., Chalmers J.D. Simplification of the IDSA/ATS criteria for severe CAP using meta-analysis and observational data. Eur Respir J. 2014; 43(3): 842–51. DOI: 10.1183/09031936.00089513
  63. Charles P.G.P., Wolfe R., Whitby M., et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008; 47(3): 375–84. DOI: 10.1086/589754
  64. Houck P.M., Bratzler D.W., Nsa W., et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004; 164(6): 637–44. DOI: 10.1001/archinte.164.6.637
  65. Lee J.S., Giesler D.L., Gellad W.F., et al. Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review. JAMA 2016; 315(6): 593–602. DOI: 10.1001/jama.2016.0115
  66. Daniel P., Rodrigo C., McKeever T.M., et al. Time to first antibiotic and mortality in adults hospitalised with community-acquired pneumonia: a matched-propensity analysis. Thorax. 2016; 71(6): 568–70. DOI: 10.1136/thoraxjnl-2015-207513
  67. Sligl W.I., Hoang H., Eurich D.T., et al. Macrolide use in the treatment of critically ill patients with pneumonia: incidence, correlates, timing and outcomes. Can J Infect Dis Med Microbiol. 2013; 24(4): e107–12. DOI: 10.1155/2013/652512
  68. Wiersinga W.J., BontenM.J., Boersma W.G., et al. Management of community-acquired pneumonia in adults: 2016 guideline update from the Dutch Working Party on Antibiotic Policy (SWAB) and Dutch Association of Chest Physicians (NVALT). The Netherlands Journal of Medicine 2018; 76(1): 4–13.
  69. Liu V.X., Fielding-Singh V., Greene J.D., et al. The Timing of Early Antibiotics and Hospital Mortality in Sepsis. Am J Respir Crit Care Med. 2017; 196(7): 856–63. DOI: 10.1164/rccm.201609-1848OC
  70. Rodríguez A., Mendia A., Sirvent J.M., et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med. 2007; 35(6): 1493–8. DOI: 10.1097/01.CCM.0000266755.75844.05
  71. Gattarello S., Borgatta B., Sole-Violan J., et al. Zaragoza pneumonia: impact of improving antibiotic strategies (2000–2013). Chest. 2014; 146(1): 22–31. DOI: 10.1378/chest.13-1531
  72. De la Calle C., Ternavasio-de la Vega H.G., Morata L., et al. Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: a propensity score analysis. J Infection. 2018; 76(4): 342–7. DOI: 10.1016/j.jinf.2018.01.003
  73. Gattarello S., Lagunes L., Vidaur L., et al. Improvement of antibiotic therapy and ICU survival in severe non-pneumococcal community-acquired pneumonia: a matched case-control study. Crit Care. 2015; 19(1): 335. DOI: 10.1186/s13054-015-1051-1
  74. Torres A., Garau J., Arvis P., et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study — a randomized clinical trial. Clin Infect Dis. 2008; 46(10): 1499–509. DOI: 10.1086/587519
  75. Leroy O., Saux P., Bédos J.P., et al. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest. 2005; 128(1): 172–83. DOI: 10.1378/chest.128.1.172
  76. Garnacho-Montero J., Barrero-García I., Gómez-Prieto M., et al. Severe community-acquired pneumonia: current management and future therapeutic alternatives. Expert Rev Anti Infect Ther. 2018; 16(9): 667–77. DOI: 10.1080/14787210.2018.1512403
  77. КозловР.С., Голуб А.В. Цефтаролин — sui generis. Клиническая микробиология и антимикробная химиотерапия. 2013; 2: 124–30. [Kozlov R.S., Golub A.V. Ceftaroline — “Sui Generis” Clin Microbiol Antimicrob Chemiother. 2013; 2: 124–30. (In Russ)]
  78. Sader H.S., Flamm R.K., Streit J.M., et al. Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America. International Journal of Infectious Diseases 2018; 77: 82–6. DOI: 10.1016/j.ijid.2018.10.004
  79. Shorr A.F., Kollef M., Eckburg P.B., et al. Assessment of Ceftaroline Fosamil in the Treatment of Community-Acquired Bacterial Pneumonia Due to Streptococcus Pneumoniae: Insights From Two Randomized Trials. Diagn Microbiol Infect Dis. 2013; 75(3): 298–303. DOI: 10.1016/j.diagmicrobio.2012.12.002
  80. Restrepo M.I., Babu B.L., Reyes L.F., et al. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. Eur Respir J. 2018; 52(2): pii 1701190. DOI: 10.1183/13993003.01190-201
  81. Loewen K., Schreiber Y., Kirlew M., et al. Community-associated methicillin resistant Staphylococcus aureus infection: Literature review and clinical update. Can Fam Physician. 2017; 63(7): 512–20.
  82. Shindo Y., Sato S., Maruyama E., et al. Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital. Chest. 2009; 135(3): 633–40. DOI: 10.1378/chest.08-1357.
  83. Prina E., Ranzani O.T., Polverino E., et al. Risk factors associated with potentially antibiotic- resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc. 2015; 12(2): 153–60. DOI: 10.1513/AnnalsATS.201407-305OC
  84. Aliberti S., Di Pasquale M., Zanaboni A.M., et al. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin. Infect. 2012; 54(4): 470–8. DOI: 10.1093/cid/cir840
  85. González-Castillo J., Martín-Sánchez F.J., Llinares P., et al. Guidelines for the management of community-acquired pneumonia in the elderly patient. Rev Esp Quimioter. 2014; 27(1): 69–86.
  86. von Baum H., Welte T., Marre R., et al. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: Diagnosis, incidence and predictors. Eur Respir J. 2010; 35(3): 598–605. DOI: 10.1183/09031936.00091809
  87. Torres А., Chalmers J.D., Dela Cruz C.S., et al. Challenges in severe community-acquired pneumonia: a point-of-view review. Intensive Care Med. 2019; 45(2): 159–71. DOI: 10.1007/s00134-019-05519-y
  88. Webb B.J., Dascomb K., Stenehjem E., et al. Predicting risk of drug-resistant organisms in pneumonia: moving beyond the HCAP model. Respir Med. 2015; 109(1): 1–10. DOI: 10.1016/j.rmed.2014.10.017
  89. Lee N., Choi K.W., Chan P.K., et al. Outcomes of adults hospitalised with severe influenza. Thorax. 2010; 65(6): 510–15. DOI: 10.1136/thx.2009.130799
  90. Dobson J., Whitley R.J., Pocock S., et al. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet. 2015; 385(9979): 1729–37. DOI: 10.1016/S0140-6736(14)62449-1
  91. Lee E.H., Wu C., Lee E.U., et al. Fatalities associated with the 2009 H1N1 influenza A virus in New York city. Clin Infect Dis. 2010; 50(11): 1498–504. DOI: 10.1086/652446
  92. Louie J.K., Yang S., Acosta M., et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis. 2012; 55(9): 1198–204. DOI: 10.1093/cid/cis636
  93. Murray R.J., Robinson J.O., White J.N., et al. Community-acquired pneumonia due to pandemic A(H1N1)2009 influenzavirus and methicillin resistant Staphylococcus aureus co-infection. PLoS One. 2010; 5(1): e8705. DOI: 10.1371/journal.pone.0008705
  94. Self W.H., Wunderink R.G., Williams D.J., et al. Staphylococcus aureus Community-acquired Pneumonia: Prevalence, Clinical Characteristics, and Outcomes. Clin Infect Dis. 2016; 63(3): 300–9. DOI: 10.1093/cid/ciw300
  95. Eljaaly K., Wali H., Basilim A., et al. Clinical cure with ceftriaxone versus ceftaroline or ceftobiprole in the treatment of staphylococcal pneumonia: a systematic review and meta-analysis. Int J Antimicrob Agents. 2019; 54(2): 149–53. DOI: 10.1016/j.ijantimicag.2019.05.023
  96. КозловР.С., Рачина С.А., Захаренко С.М. Общие принципы антимикробной химиотерапии инфекционных больных. В кн: Руководство по инфекционным болезням. Под ред. Ю.В. Лобзина, К.В. Жданова. 4-е изд., доп. и перераб. СПб.: ООО «Издательство Фолиант», 2011: 58–106. [Kozlov R.S., Rachina S.A., Zakharenko S.M. General principles of antimicrobial chemotherapy for patients with infectious diseases. In: Guide to infectious diseases. Ed. by Yu.V. Lobzin, K.V. Zhdanov. 4 ed., add. and revised. St. Petersburg: LLC “Foliant Publishing House”; 2011: 58–106. (In Russ)]
  97. Metlay J.P., Watere G.W., Long A.C., et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019; 200(7): e45–e67. DOI: 10.1164/rccm.201908-1581ST
  98. Leone M., Bechis C., Baumstarck K., et al. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive Care Med. 2014; 40(10): 1399–408. DOI: 10.1007/s00134-014-3411-8
  99. Gutierrez-Pizarraya A., Leone M., Garnacho-Montero J., et al. Collaborative approach of individual participant data of prospective studies of de-escalation in non-immunosuppressed critically ill patients with sepsis. Expert Rev Clin Pharmacol. 2017; 10(4): 457–65. DOI: 10.1080/17512433.2017.1293520
  100. Dimopoulos G., Matthaiou D.K., Karageorgopoulos D.E., et al. Short-versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs. 2008; 68(13): 1841–54. DOI: 10.2165/00003495-200868130-00004
  101. Tansarli G.S., Mylonakis E. Systematic review and meta-analysis of the efficacy of short-course antibiotic treatments for community- acquired pneumonia in adults. Antimicrob Agents Chemother. 2018; 62(9): e00635–18. DOI: 10.1128/AAC.00635-18
  102. Zasowski E., Butterfield J.M., McNutt L.A., et al. Relationship between time to clinical response and outcomes among Pneumonia Outcomes Research Team (PORT) risk class III and IV hospitalized patients with community-acquired pneumonia who received ceftriaxone and azithromycin. Antimicrob Agents Chemother. 2014; 58(7): 3804–13. DOI: 10.1128/AAC.02632-13
  103. Garin N., Felix G., Chuard C., et al. Predictors and implications of early clinical stability in patients hospitalized for moderately severe community-acquired pneumonia. PLoS One. 2016; 11(6): e0157350. DOI: 10.1371/journal.pone.0157350
  104. Murad A., Li P.Z., Dial S., Shahin J. The role of noninvasive positive pressure ventilation in community-acquired pneumonia. Journal of Critical Care. 2015; 30(1): 49–54. DOI: 10.1016/j.jcrc.2014.09.021
  105. Besen BAMP, Park M., Ranzani O.T. Noninvasive ventilation in critically ill very old patients with pneumonia: A multicenter retrospective cohort study. PLoS ONE. 2021; 16: e0246072. DOI: 10.1371/journal.pone.0246072
  106. Barrot L., Asfar P., Mauny F., et al. Liberal or Conservative Oxygen Therapy for Acute Respiratory Distress Syndrome. N Engl J Med. 2020; 382(11): 999–1008. DOI: 10.1056/NEJMoa1916431
  107. АвдеевС.Н. Ургентная кислородотерапия. Вестник анестезиологии и реаниматологии. 2011; 3: 42–51 [Avdeev S.N. Urgent oxygen therapy. Bulletin of Anesthesiology and Reanimatology. 2011; 3: 42–51. (In Russ)]
  108. Tobin M.J. Basing Respiratory Management of Coronavirus on Physiological Principles. Am J Respir Crit Care Med. 2020. DOI: 10.1164/rccm.202004-1076ED
  109. Yaroshetskiy A.I., Avdeev S.N., Konanykhin V.D. Acute Respiratory Distress Syndrome in COVID-19: Do All These Patients Definitely Require Intubation and Mechanical Ventilation? Am J Respir Crit Care Med. 2020; 202(10): 1480–1. DOI: 10.1164/rccm.202007-2713LE
  110. ЯрошецкийА.И., Власенко А.В., Грицан А.И. и др. Применение неинвазивной вентиляции легких (2-й пересмотр). Анестезиология и реаниматология. 2019; 6: 5–19. DOI: 10.17116/anaesthesiology20190615 [Yaroshetskiy A.I., Vlasenko A.V., Gritsan A.I., et al. Non-invasive respiratory support (2nd) Russian Journal of Anaesthesiology and Reanimatology. 2019; 6: 5–19. (In Russ)]
  111. Frat J.P., Thille A.W., Mercat A., et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015; 372(23): 2185–96. DOI: 10.1056/NEJMoa1503326
  112. Grieco D.L., Menga L.S., Raggi V., et al. physiological comparison of high-flow nasal cannula and helmet noninvasive ventilation in acute hypoxemic respiratory failure. Am J Respir Crit Care Med. 2020; 201(3): 303–12. DOI: 10.1164/rccm.201904-0841OC
  113. LʼHer E., Deye N., Lellouche F., et al. Physiologic effects of noninvasive ventilation during acute lung injury. Am J Respir Crit Care Med. 2005; 172(9): 1112–8. DOI: 10.1164/rccm.200402-226OC
  114. Cosentini R., Brambilla A.M., Aliberti S., et al. Helmet continuous positive airway pressure vs oxygen therapy to improve oxygenation in community-acquired pneumonia: a randomized, controlled trial. Chest. 2010; 138(1): 114–20. DOI: 10.1378/chest.09-2290
  115. Brambilla A.M., Aliberti S., Prina E., et al. Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia. Intensive Care Med. 2014; 40(7): 942–9. DOI: 10.1007/s00134-014-3325-5
  116. Ferreyro B.L., Angriman F., Munshi L., et al. Association of Noninvasive Oxygenation Strategies With All-Cause Mortality in Adults With Acute Hypoxemic Respiratory Failure: A Systematic Review and Meta-analysis. JAMA. 2020; 324(1): 57–67. DOI: 10.1001/jama.2020.9524
  117. Carteaux G., Millán-Guilarte T., De Prost N., et al. Failure of Noninvasive Ventilation for De Novo Acute Hypoxemic Respiratory Failure: Role of Tidal Volume. Crit Care Med. 2016; 44(2): 282–90. DOI: 10.1097/CCM.0000000000001379
  118. Frat J.P., Ragot S., Coudroy R., et al. Predictors of Intubation in Patients With Acute Hypoxemic Respiratory Failure Treated With a Noninvasive Oxygenation Strategy. Crit Care Med. 2018; 46(2): 208–15. DOI: 10.1097/CCM.0000000000002818
  119. Thille A.W., Yoshida T. High Pressure versus High Flow: What Should We Target in Acute Respiratory Failure? Am J Respir Crit Care Med. 2020; 201(3): 265–6. DOI: 10.1164/rccm.201911-2196ED
  120. Guerin C., Reignier J., Richard J.C., et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013; 368(23): 2159–68. DOI: 10.1056/NEJMoa1214103
  121. Munshi L., Del Sorbo L., Adhikari N.K.J., et al. Prone Position for Acute Respiratory Distress Syndrome. A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2017; 14(Suppl_4): S280–S288. DOI: 10.1513/AnnalsATS.201704-343OT
  122. Dreyfuss D., Djedaini K., Lanore J.J., et al. A comparative study of the effects of almitrine bismesylate and lateral position during unilateral bacterial pneumonia with severe hypoxemia. Am Rev Respir Dis. 1992; 146(2): 295–9. DOI: 10.1164/ajrccm/146.2.295
  123. Scaravilli V., Grasselli G., Castagna L., et al. Prone positioning improves oxygenation in spontaneously breathing non-intubated patients with hypoxemic acute respiratory failure: a retrospective study. J Crit Care. 2015; 30(6): 1390–4. DOI: 10.1016/j.jcrc.2015.07.008
  124. Kohno S., Seki M., Takehara K., et al. Prediction of requirement for mechanical ventilation in community-acquired pneumonia with acute respiratory failure: a multicenter prospective study. Respiration. 2013; 85(1): 27–35. DOI: 10.1159/000335466
  125. Brochard L., Slutsky A., Pesenti A. Mechanical ventilation to minimize progression of lung injury in acute respiratory failure. Am J Respir Crit Care Med. 2017; 195(4): 438–42. DOI: 10.1164/rccm.201605-1081CP
  126. Tonelli R., Fantini R., Tabbì L., et al. Early inspiratory effort assessment by esophageal manometry early predicts noninvasive ventilation outcome in de novo respiratory failure: a pilot study. Am J Respir Crit Care Med. 2020; 202(4): 558–67. DOI: 10.1164/rccm.201912-2512OC
  127. Apigo M., Schechtman J., Dhliwayo N., et al. Development of a work of breathing scale and monitoring need of intubation in COVID-19 pneumonia. Crit Care. 2020; 24: 477. DOI: 10.1186/s13054-020-03176-y
  128. Demoule A., Jung B., Prodanovic H., et al. Diaphragm dysfunction on admission to the intensive care unit. Prevalence, risk factors, and prognostic impact-a prospective study. Am J Respir Crit Care Med. 2013; 188(2): 213–19. DOI: 10.1164/rccm.201209-1668OC
  129. MacIntyre R. Indications for mechanical ventilation. In: Oxford Textbook Of Critical Care. Eds: Webb A., Angus D., Finfer S., Gattinoni L. and Singer M. Oxford University Press, 2016. DOI: 10.1093/med/9780199600830.003.0091
  130. Behazin N., Jones S.B., Cohen R.I., Loring S.H. Respiratory restriction and elevated pleural and esophageal pressures in morbid obesity. J Appl Physiol. 2010; 108(1): 212–18. DOI: 10.1152/japplphysiol.91356.2008
  131. Chiumello D., Carlesso E., Cadringher, et al. Lung stress and strain during mechanical ventilation for acute respiratory distress syndrome. Am J Respir Crit Care Med. 2008; 178(4): 346–55. DOI: 10.1164/rccm.200710-1589OC
  132. Dreyfuss D., Saumon G. Ventilator-induced lung injury: Lessons from experimental studies. Am J Respir Crit Care Med. 1998; 157(1): 294–323. DOI: 10.1164/ajrccm.157.1.9604014
  133. Gattinoni L., Chiumello D., Carlesso E., Valenza F. Bench-to-bedside review: chest wall elastance in acute lung injury/acute respiratory distress syndrome patients. Crit Care. 2004; 8(5): 350–5. DOI: 10.1186/cc2854
  134. ARDS Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. New Engl J Med. 2000; 342(18): 1301–8. DOI: 10.1056/NEJM200005043421801
  135. Briel M., Meade M., Mercat A., et al. Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. JAMA. 2010; 303(9): 865–73. DOI: 10.1001/jama.2010.218
  136. Gattinoni L., Pelosi P., Suter P.M., et al. Acute respiratory distress syndrome caused by pulmonary and extrapulmonary disease. Different syndromes? Am J Respir Crit Care Med. 1998; 158(1): 3–11. DOI: 10.1164/ajrccm.158.1.9708031
  137. Writing Group for the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial (ART) Investigators, Cavalcanti A.B., Suzumura ÉA, et al. Effect of Lung Recruitment and Titrated Positive End-Expiratory Pressure (PEEP) vs Low PEEP on Mortality in Patients With Acute Respiratory Distress Syndrome: A Randomized Clinical Trial. JAMA. 2017; 318(14): 1335–45. DOI: 10.1001/jama.2017.14171
  138. Combes A., Hajage D., Capellier G., et al. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome. N Engl J Med. 2018; 378(21): 1965–75. DOI: 10.1056/NEJMoa1800385
  139. Patroniti N., Bonatti G., Senussi T., Robba C. Mechanical ventilation and respiratory monitoring during extracorporeal membrane oxygenation for respiratory support. Ann Transl Med. 2018; 6(19): 386. DOI: 10.21037/atm.2018.10.11
  140. Annane D., Sebille V., Charpentier C., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002; 288: 862–71. DOI: 10.1001/jama.288.7.862
  141. Martin-Loeches I., Torres A. Corticosteroids for CAP, influenza and COVID-19: when, how and benefits or harm? Eur Respir Rev 2021; 30: 200 346 DOI: 10.1183/16000617.0346–2020.
  142. Mismetti P., Laporte-Simitsidis S., Tardy B., et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000; 83:14–9.
  143. Frenck R.W.Jr, Gurtman A., Rubino J., et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol. 2012; 19(8): 1296–303. DOI: 10.1128/CVI.00176-12
  144. Schwarz T.F., Flamaing J., Rümke H.C., et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥ 65 years. Vaccine. 2011; 29(32): 5195–202. DOI: 10.1016/j.vaccine.2011.05.031
  145. Ofori-Anyinam O., Leroux-Roels G., Drame M., et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥ 50 years of age: Results from a phase III, randomized, non-inferiority trial. Vaccine. 2017; 35(46): 6321–8. DOI: 10.1016/j.vaccine.2017.09.012
  146. Stacey H.L., Rosen J., Peterson J.T., et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. Human Vaccines and Immunotherapeutics 2019; 15(3): 530–9. DOI: 10.1080/21645515.2018.1532249
  147. Klein N.P., Peyrani P., Yacisin C., et al. A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age. Vaccine. 2021; 39(38): 5428–35. DOI:1016/j.vaccine.2021.07.004
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright (c) 2021 ANNALS OF CRITICAL CARE


Download data is not yet available.